NASDAQ:TPTX - Turning Point Therapeutics Stock Price, Forecast & News

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TPTX shares have increased by 10.2% and is now trading at $44.66. View which stocks have been mosted impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Turning Point Therapeutics.

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 29th 2020. View our earnings forecast for Turning Point Therapeutics.

Turning Point Therapeutics (NASDAQ:TPTX) released its earnings results on Monday, March, 16th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.67) by $0.09. View Turning Point Therapeutics' earnings history.

8 brokers have issued 12 month price objectives for Turning Point Therapeutics' stock. Their forecasts range from $48.00 to $72.00. On average, they expect Turning Point Therapeutics' share price to reach $59.25 in the next twelve months. This suggests a possible upside of 32.7% from the stock's current price. View analysts' price targets for Turning Point Therapeutics.

Headlines about TPTX stock have trended positive recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Turning Point Therapeutics earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutTurning Point Therapeutics.

Some companies that are related to Turning Point Therapeutics include Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Reata Pharmaceuticals (RETA), Amarin (AMRN), Forty Seven (FTSV), United Therapeutics (UTHR), Evotec (EVTCY), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX) and Blueprint Medicines (BPMC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include Axsome Therapeutics (AXSM), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Immunomedics (IMMU), Intel (INTC), Sarepta Therapeutics (SRPT), Voyager Therapeutics (VYGR), AbbVie (ABBV), Enterprise Products Partners (EPD) and Energy Transfer LP Unit (ET).

(TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TPTX stock can currently be purchased for approximately $44.66.

Turning Point Therapeutics has a market capitalization of $1.60 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Turning Point Therapeutics employs 50 workers across the globe. View additional information about Turning Point Therapeutics.

The official website for Turning Point Therapeutics is http://www.tptherapeutics.com/.

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]